Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals (Nasdaq: APLS), a global biopharmaceutical company specializing in complement therapies, has announced the approval of equity inducement awards for one new employee. The grants, made outside the company's 2017 Stock Incentive Plan but under the 2020 Inducement Stock Incentive Plan, were approved on August 1, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
The employee received 1,015 restricted stock units (RSUs). These RSUs will vest over four years, with 25% vesting on the first anniversary of the grant date and an additional 25% vesting annually thereafter, contingent on the employee's continued employment.
Apellis Pharmaceuticals (Nasdaq: APLS), una società biofarmaceutica globale specializzata in terapie complementari, ha annunciato l'approvazione di premi di indennità azionaria per un nuovo dipendente. I riconoscimenti, concessi al di fuori del Piano di Incentivi Azionari del 2017 ma sotto il Piano di Incentivi Azionari per Induzione del 2020, sono stati approvati il 1 agosto 2024, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Il dipendente ha ricevuto 1.015 unità azionarie vincolate (RSU). Queste RSU matureranno nel corso di quattro anni, con il 25% che matura alla prima ricorrenza dell'mdata di concessione e un ulteriore 25% che matura annualmente successivamente, a condizione che il dipendente continui a essere impiegato.
Apellis Pharmaceuticals (Nasdaq: APLS), una compañía biofarmacéutica global especializada en terapias de complemento, ha anunciado la aprobación de premios de incentivación de acciones para un nuevo empleado. Las concesiones, realizadas fuera del Plan de Incentivos Accionarios de 2017 pero bajo el Plan de Incentivos Accionarios por Inducción de 2020, fueron aprobadas el 1 de agosto de 2024, de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.
El empleado recibió 1,015 unidades de acciones restringidas (RSUs). Estas RSUs se otorgarán durante cuatro años, con un 25% otorgado en el primer aniversario de la fecha de concesión y un 25% adicional otorgándose anualmente a partir de ahí, dependiendo de la continuidad del empleo del empleado.
Apellis Pharmaceuticals (Nasdaq: APLS)는 보완 요법을 전문으로 하는 글로벌 생명공학 회사로서, 새로운 직원에게 주식 유인 보상을 승인했다고 발표했습니다. 이 보상은 2017년 주식 인센티브 플랜 이외에서 제공되었지만 2020년 유인 주식 인센티브 플랜에 따라 승인되었습니다. 이는 2024년 8월 1일에 승인되었으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 이루어진 것입니다.
직원은 1,015 개의 제한 주식 단위(RSU)를 받았습니다. 이 RSU는 4년에 걸쳐 성과가 발생하며, 최초 부여일의 1주년에는 25%가 발생하고, 이후 매년 추가로 25%가 발생하며, 이는 직원의 계속 고용 여부에 따릅니다.
Apellis Pharmaceuticals (Nasdaq: APLS), une entreprise biopharmaceutique mondiale spécialisée dans les thérapies complémentaires, a annoncé l'approbation de primes d'incitation en actions pour un nouvel employé. Les attributions, faites en dehors du Plan d'Incitations en Actions de 2017 mais dans le cadre du Plan d'Incitations en Actions par Induction de 2020, ont été approuvées le 1er août 2024, conformément à la Règle de Cotation Nasdaq 5635(c)(4).
L'employé a reçu 1 015 unités d'actions restreintes (RSUs). Ces RSUs se libéreront sur une période de quatre ans, avec 25 % se libérant lors du premier anniversaire de la date d'attribution et un supplément de 25 % qui se libérera annuellement par la suite, sous réserve de la poursuite de l'emploi de l'employé.
Apellis Pharmaceuticals (Nasdaq: APLS), ein globales biopharmazeutisches Unternehmen, das sich auf Komplementtherapien spezialisiert hat, hat die Genehmigung von Eigenkapitalanreizen für einen neuen Mitarbeiter bekannt gegeben. Die Zuwendungen, die außerhalb des Aktienanreizplans von 2017, jedoch im Rahmen des Anreiz-Aktienplans von 2020 gewährt wurden, wurden am 1. August 2024 gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
Der Mitarbeiter erhielt 1.015 eingeschränkte Aktieneinheiten (RSUs). Diese RSUs werden über einen Zeitraum von vier Jahren fällig, wobei 25 % am ersten Jahrestag des Ausgabetages und weitere 25 % anschließend jährlich fällig werden, vorausgesetzt, der Mitarbeiter bleibt weiterhin angestellt.
- Apellis is attracting new talent with equity incentives
- The company is complying with Nasdaq listing rules for equity grants
- None.
WALTHAM, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to one new employee with a grant date of August 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received 1,015 restricted stock units (RSUs). Each RSU will vest as to
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the data analyses reported in this release indicate an apparent positive effect that is greater than the actual positive effect, and other factors discussed in the “Risk Factors” section of Apellis’ Annual Report on Form 10-K with the Securities and Exchange Commission on February 27, 2024 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Media Contact:
Tracy Vineis
media@apellis.com
617.420.4839
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
How many restricted stock units (RSUs) did Apellis Pharmaceuticals (APLS) grant to the new employee?
What is the vesting schedule for the RSUs granted by Apellis Pharmaceuticals (APLS) on August 1, 2024?
Under which plan were the equity inducement awards granted by Apellis Pharmaceuticals (APLS)?
Which Nasdaq rule did Apellis Pharmaceuticals (APLS) comply with for these equity grants?
